TY - JOUR
T1 - Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors
T2 - Comparison with the effectiveness of cabergoline treatment
AU - Pivonello, Rosario
AU - Matrone, Carmela
AU - Filippella, Mariagiovanna
AU - Cavallo, Luigi M.
AU - Di Somma, Carolina
AU - Cappabianca, Paolo
AU - Colao, Annamaria
AU - Annunziato, Lucio
AU - Lombardi, Gaetano
PY - 2004/4
Y1 - 2004/4
N2 - The aim of this study was to correlate dopamine receptors and D2 isoform expression with the cabergoline effect on α-subunit secretion in vitro and tumor mass in vivo in clinically nonfunctioning pituitary tumors. Eighteen patients were subjected to neurosurgery, and a tumor sample was used for dopamine receptor and D2 isoform expression evaluation by RT-PCR and the in vitro functional studies. After neurosurgery, nine of 18 patients with persistent tumor were treated with cabergoline and tumor mass was evaluated before and after 1 yr treatment. D2 receptor was expressed in 67% of cases. D2long was found in 50%, D2short in 17%, and both D2 isoforms in 33% of cases. D4 receptor was also expressed in 17% of cases. The in vitro inhibition of α-subunit concentration was found in 56% of cases and was associated with D2 expression (χ2 = 5.6; P <0.05). After 1 yr of cabergoline treatment, tumor shrinkage was evident in 56% of patients and was associated with D2 expression (χ2 = 5.6; P <0.05). The expression of D2short rather than D2long isoform is associated with the most favorable response of the tumor to cabergoline treatment. In conclusion, this study demonstrates D2 receptor expression and function in nearly 70% of cases, suggesting a role of this drug in the treatment schedule of clinically nonfunctioning pituitary tumors.
AB - The aim of this study was to correlate dopamine receptors and D2 isoform expression with the cabergoline effect on α-subunit secretion in vitro and tumor mass in vivo in clinically nonfunctioning pituitary tumors. Eighteen patients were subjected to neurosurgery, and a tumor sample was used for dopamine receptor and D2 isoform expression evaluation by RT-PCR and the in vitro functional studies. After neurosurgery, nine of 18 patients with persistent tumor were treated with cabergoline and tumor mass was evaluated before and after 1 yr treatment. D2 receptor was expressed in 67% of cases. D2long was found in 50%, D2short in 17%, and both D2 isoforms in 33% of cases. D4 receptor was also expressed in 17% of cases. The in vitro inhibition of α-subunit concentration was found in 56% of cases and was associated with D2 expression (χ2 = 5.6; P <0.05). After 1 yr of cabergoline treatment, tumor shrinkage was evident in 56% of patients and was associated with D2 expression (χ2 = 5.6; P <0.05). The expression of D2short rather than D2long isoform is associated with the most favorable response of the tumor to cabergoline treatment. In conclusion, this study demonstrates D2 receptor expression and function in nearly 70% of cases, suggesting a role of this drug in the treatment schedule of clinically nonfunctioning pituitary tumors.
UR - http://www.scopus.com/inward/record.url?scp=1942440916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1942440916&partnerID=8YFLogxK
U2 - 10.1210/jc.2003-030859
DO - 10.1210/jc.2003-030859
M3 - Article
C2 - 15070930
AN - SCOPUS:1942440916
VL - 89
SP - 1674
EP - 1683
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 4
ER -